

doi: 10.13241/j.cnki.pmb.2020.14.037

不同剂量舒芬太尼对直肠癌患者全麻气管插管应激反应和血流动力学的影响*

梁东锋¹ 邓海波¹ 王秋锋¹ 姚远² 梁启胜³

(1 安徽省阜阳市人民医院麻醉科 安徽 阜阳 236000; 2 安徽省阜阳市人民医院普外科 安徽 阜阳 236000;

3 安徽省蚌埠医学院第一附属医院麻醉科 安徽 蚌埠 233004)

摘要 目的:研究不同剂量舒芬太尼对直肠癌患者全麻气管插管应激反应和血流动力学的影响。**方法:**选择 2017 年 1 月~2019 年 12 月在我院择期进行腹腔镜直肠癌切除术患者 90 例作为研究对象,依据随机数字表法分为 A 组、B 组、C 组,每组各 30 例。A 组:0.4 μg/kg 舒芬太尼,B 组:0.5 μg/kg 舒芬太尼,C 组:0.6 μg/kg 舒芬太尼,观察并比较各组气管插管应激反应,插管前后血流动力学指标,麻醉恢复指标以及不良反应的发生情况。**结果:**插管后 1 min 及 3 min,各组去甲肾上腺素(NA)、肾上腺素(AD)水平均较基础值显著上升,A 组以上指标依次高于 B 组、C 组($P<0.05$);A 组、B 组心率、平均动脉压水平均较基础值上升,A 组以上指标高于 B 组,C 组以上指标低于基础值($P<0.05$);A 组、B 组 BIS 值均较基础值下降,A 组以上指标高于 B 组、C 组($P<0.05$)。A 组、B 组自主呼吸恢复时间、呼吸睁眼时间和拔管时间比较无统计学差异($P>0.05$),但均短于 C 组($P<0.05$)。A 组呛咳率显著高于 B 组、C 组,C 组恶心呕吐率高于 A 组、B 组($P<0.05$)。**结论:**0.5 μg/kg 舒芬太尼能够减轻直肠癌全麻气管插管应激反应,减少血流动力学波动,且无苏醒延长,不增加药物不良反应。

关键词:直肠癌;不同剂量舒芬太尼;气管插管应激反应;血流动力学

中图分类号:R735.37;R614 文献标识码:A 文章编号:1673-6273(2020)14-2766-05

Effects of Different Doses of Sufentanil on the Stress Response and Hemodynamics of Tracheal Intubation under General Anesthesia in the Patients with Rectal Cancer*

LIANG Dong-feng¹, DENG Hai-bo¹, WANG Qiu-feng¹, YAO Yuan², LIANG Qi-sheng³

(1 Department of Anesthesiology, Fuyang people's Hospital, Anhui Province, Fuyang, Anhui, 236000, China; 2 General surgery department of Fuyang people's Hospital of Anhui Province, Fuyang, Anhui, 236000, China; 3 Department of Anesthesiology, the First Affiliated Hospital of Bengbu Medical College, Anhui Province, Bengbu, Anhui, 233004, China)

ABSTRACT Objective: To study the effects of different doses of sufentanil on the stress response and hemodynamics of rectal cancer patients undergoing tracheal intubation under general anesthesia. **Methods:** Ninety patients undergoing elective laparoscopic rectal cancer resection in our hospital from January 2017 to December 2019 were selected as research objects and divided into group A, group B and group C according to random number table method, with 30 cases in each group. Group A: 0.4 μg/kg sufentanil; Group B: 0.5 μg/kg sufentanil; Group C: 0.6 μg/kg sufentanil. The stress response, hemodynamic index before and after intubation, anaesthesia recovery index and incidence of adverse reactions were observed and compared between different groups. **Results:** At 1 min and 3 min after intubation, the levels of norepinephrine (NA) and epinephrine (AD) in each group were significantly increased compared with the basal values, the above indexes in group A were successively higher than those in group B and group C ($P<0.05$). The heart rate and average arterial pressure of group A and group B were all higher than the baseline values, which were higher in group A than those of group B, while those of group C were lower than the baseline values ($P<0.05$). The BIS values of group A and group B decreased from the base values, and the above indexes of group A were higher than those of group B and group C ($P<0.05$). There was no statistically significant difference between group A and group B in the recovery time of spontaneous breathing, time of respiratory opening and time of extubation ($P>0.05$), but all of them were shorter than group C ($P<0.05$). The rate of choking in group A was significantly higher than that in group B and group C, and the rate of nausea and vomiting in group C was significantly higher than that in group A and group B ($P<0.05$). **Conclusion:** 0.5 μg/kg sufentanil can reduce the stress response of tracheal intubation under general anesthesia in rectal cancer, reduce the fluctuation of hemodynamics, and do not prolong resuscitation and increase the adverse drug reaction.

Key words: Rectal Cancer; Different doses of sufentanil; Stress reaction of tracheal intubation; Hemodynamics

* 基金项目:安徽省自然科学基金项目(1608085MH198)

作者简介:梁东锋(1976-),男,本科,副主任医师,研究方向:心脏手术麻醉,高龄患者手术麻醉和小儿麻醉,

E-mail: sexiazhaoxia@163.com,电话:13956813904

(收稿日期:2020-02-25 接受日期:2020-03-21)

Chinese Library Classification(CLC): R735.37; R614 Document code: A

Article ID: 1673-6273(2020)14-2766-05

前言

直肠癌为消化道最常见的恶性肿瘤之一,目前其治疗以外科手术为主。近年来,腹腔镜直肠癌手术已成为首选治疗术式,较传统开腹直肠癌术具有明显优势^[1,2]。但全麻气管插管机械刺激可经神经内分泌作用机制导致机体发生强烈的应激反应,能够增加肺血管阻力和平均肺动脉压力,引起血流动力学变化^[3,4]。临床研究报道^[5,6]全麻气管插管时给予阿片类药物能够减少或避免机体的应激反应,但其一般具有多种药理作用。舒芬太尼为阿片类的代表药物,具有易透过血脑屏障、和阿片受体亲和力强、镇痛作用强等特点,现已广泛用于麻醉诱导及辅助麻醉。但有研究显示^[7,8]舒芬太尼的药理作用有一定的剂量依赖性,其安全剂量和效果尚未达成共识。本研究主要分析不同剂量舒芬太尼对直肠癌患者全麻气管插管应激反应和血流动力学影响,结果报道如下。

1 资料与方法

1.1 一般资料

选择 90 例腹腔镜直肠癌切除术患者为研究对象,纳入标准^[9]:TNM 分期: I ~ II 期;美国麻醉师协会(aso class asa, ASA): I ~ II 级;凝血功能正常;无全麻禁忌证;患者知情同意本研究;年龄 31~86 岁。排除标准:预计气管插管或拔管困难;长期阿片类药物和其他镇痛药物史;酒精、药物滥用史;严重心、肝肾等疾病;妊娠或哺乳期妇女。所有患者依据随机数字表法分为 A 组、B 组、C 组,每组各 30 例。A 组男 17 例,女 13 例;年龄(57.18 ± 6.44)岁;体质指数(22.86 ± 1.41)kg/m²;TNM 分期: I 期 24 例、II 期 6 例;ASA 分级: I 级 22 例、II 级 8 例。B 组男 20 例,女 10 例;年龄(56.94 ± 7.01)岁;体质指数(22.71 ± 1.53)kg/m²;TNM 分期: I 期 19 例、II 期 11 例;ASA 分级: I 级 18 例、II 级 12 例。C 组男 18 例,女 12 例;年龄(57.33 ± 5.91)岁;体质指数(22.62 ± 1.47)kg/m²;TNM 分期: I 期 19 例、II 期 11 例;ASA 分级: I 级 21 例、II 级 9 例。各组基线资料比较无统计学差异($P>0.05$),具有可比性。

1.2 麻醉方法

所有患者均予以经口气管插管全凭静脉麻醉,术前 30 min 肌肉注射 0.01 mg/kg 阿托品和 0.1~0.2 mg/kg 安定。进入麻醉室后予以面罩吸氧,取监护仪监测脉搏血氧饱和度、无创动脉血压和心电图等,开放静脉,取 0.08 mg/kg 安定,局麻下予以桡动脉穿刺置管测压,取 10 min 后稳定的心率和平均动脉压为基础值。麻醉诱导: A 组: 0.4 μg/kg 舒芬太尼、B 组: 0.5 μg/kg 舒芬太尼、C 组: 0.6 μg/kg 舒芬太尼,各组均给予 0.12 mg/kg 维库溴铵,1.5 mg/kg 丙泊酚。通过面罩纯氧通气 3 min 后予以气管插管,并接通麻醉机进行机械通气,设定相应参数。麻醉维持: 微泵输注 0.05~0.2 mg/kg·min 丙泊酚,A 组微泵持续注入 0.4 μg/kg·h 舒芬太尼、B 组: 0.5 μg/kg·h 舒芬太尼,C 组: 0.6 μg/kg·h 舒芬太尼,并给予维库溴铵维持肌松。各组手术结束前 30~45 min 均停止舒芬太尼或芬太尼输注,关腹后停止异丙酚输注,术毕送入麻醉后恢复室,查看患者自主呼吸恢复时间、呼吸睁眼时间和拔管时间。

1.3 观察指标

于麻醉诱导前、插管后 1 min、3 min 采集患者静脉血 4 mL,用高效液相色谱 - 电化学法检测血浆去甲肾上腺素(Norepinephrine,NA)、肾上腺素(Adrenaline,AD)值。记录麻醉诱导前、插管后 1 min、3 min 心率、平均动脉压和脑电双频指数(bispectral index,BIS)值。观察并记录患者呛咳、恶心呕吐等不良反应的发生情况。

1.4 统计学分析

数据处理选用 SPSS18.0 软件包,计量资料用($\bar{x} \pm s$)表示,组间比较选用 t 检验,不同时间点采用方差分析,计数资料用[例(%)]表示,组间比较用 χ^2 检验比较,以 $P<0.05$ 表示差异有统计学意义。

2 结果

2.1 各组全麻气管插管前后血浆 NA、AD 水平的比较

各组基础血浆 NA、AD 水平比较无统计学差异($P>0.05$);插管后 1 min 及 3 min,各组血浆 NA、AD 水平均较基础值上升,A 组以上指标依次高于 B 组、C 组,差异有统计学意义($P<0.05$),见表 1。

表 1 各组气管插管前后血浆 NA、AD 水平的比较($\bar{x} \pm s$)Table 1 Comparison of the plasma NA and AD levels before and after tracheal intubation between different groups($\bar{x} \pm s$)

Groups	n	Time	NA(pg/mL)	AD(pg/mL)
Group A	30	Base value	152.29± 20.19	93.74± 12.18
		At 1min after intubation	216.44± 27.65 ^d	144.25± 16.71 ^d
		At 3min after intubation	211.05± 28.97 ^d	140.08± 15.95 ^d
Group B	30	Base value	154.20± 19.61	93.75± 12.55
		At 1min after intubation	183.03± 23.08 ^{ad}	126.22± 14.01 ^{ad}
		At 3min after intubation	181.01± 24.95 ^{ad}	122.61± 13.88 ^{ad}
Group C	30	Base value	153.71± 20.08	92.56± 11.84
		At 1min after intubation	171.12± 21.07 ^{abd}	110.05± 12.16 ^{abd}
		At 3min after intubation	171.94± 22.85 ^{abd}	107.94± 14.27 ^{abd}

Note: Compared with group A, ^a $P<0.05$; Compared with group B, ^b $P<0.05$; Compared with the basic values of same group, ^c $P<0.05$.

2.2 各组全麻气管插管前后血流动力学指标的比较

各组基础心率、平均动脉压及 BIS 值比较无统计学差异 ($P>0.05$)；插管后 1 min 及 3 min, A 组、B 组心率、平均动脉压

水平均较基础值上升, A 组以上指标高于 B 组、C 组, C 组以上指标低于基础值($P<0.05$)；A 组、B 组 BIS 值均较基础值下降, A 组以上指标高于 B 组、C 组($P<0.05$), 见表 2。

表 2 各组全麻气管插管前后血流动力学指标的比较($\bar{x} \pm s$)

Table 2 Comparison of the hemodynamic indexes before and after tracheal intubation between different groups($\bar{x} \pm s$)

Groups	n	Time	Heart rate(times/min)	Mean arterial pressure(mmHg)	BIS
Group A	30	Base value	74.09± 8.63	84.11± 9.66	98.71± 13.86
		At 1min after intubation	104.27± 12.14 ^d	106.32± 12.17 ^d	56.84± 7.55 ^d
		At 3min after intubation	98.33± 13.26 ^d	101.29± 13.18 ^d	55.91± 6.94 ^d
Group B	30	Base value	75.42± 8.51	83.53± 10.16	96.74± 15.01
		At 1min after intubation	94.27± 14.19 ^{ad}	95.27± 12.59 ^{ad}	48.11± 6.71 ^{ad}
		At 3min after intubation	91.33± 13.45 ^{ad}	92.66± 13.01 ^{ad}	47.75± 7.03 ^{ad}
Group C	30	Base value	74.81± 9.75	82.95± 11.21	97.52± 14.29
		At 1min after intubation	62.72± 9.13 ^{abd}	73.81± 8.75 ^{abd}	41.07± 6.03 ^{abd}
		At 3min after intubation	65.75± 8.71 ^{abd}	74.73± 9.61 ^{abd}	42.63± 6.77 ^{abd}

Note: Compared with group A, ^a $P<0.05$; Compared with group B, ^b $P<0.05$; Compared with the same group of basic values, ^d $P<0.05$.

2.3 各组麻醉恢复指标比较

A 组、B 组自主呼吸恢复时间、呼吸睁眼时间和拔管时间

比较无统计学差异 ($P>0.05$), A 组、B 组自主呼吸恢复时间、呼吸睁眼时间和拔管时间均少于 C 组($P<0.05$), 见表 3。

表 3 各组麻醉恢复指标的比较(例, %)

Table 3 Comparison of the anaesthesia recovery indexes between different groups(n,%)

Groups	n	Recovery time of spontaneous respiration(min)	Opening time of respiration (min)	Extubation time(min)
Group A	30	3.16± 0.42	6.04± 0.84	8.09± 1.22
Group B	30	3.30± 0.33	6.35± 0.75	8.53± 1.02
Group C	30	6.19± 0.82 ^a	10.85± 1.29 ^a	14.27± 1.49 ^a

Note: Compared with group A, ^a $P<0.05$.

2.4 各组不良反应发生情况的比较

A 组呛咳率高于 B 组、C 组, C 组恶心呕吐率高于 A 组、B

组($P<0.05$), 见表 4。

Table 4 Comparison of the incidence of adverse reactions between different groups(n,%)

Groups	n	Cough	Nausea and vomiting
Group A	30	4(13.33)	0(0.00)
Group B	30	0(0.00) ^a	1(3.33)
Group C	30	0(0.00) ^a	6(20.00) ^a

Note: Compared with group A, ^a $P<0.05$.

3 讨论

腹腔镜直肠癌切除术是直肠癌的主要术式, 气管插管作为一种伤害性刺激原能够导致气管内积咽喉部产生机械牵张刺激, 增加交感 - 肾上腺素系统活性, 引起神经内分泌反应^[10,11]。阿片类药物能够直接作用于应激激素前受体, 抑制应激激素释放, 且可扩张外周小血管, 抑制副交感神经的兴奋性及儿茶酚胺释放, 还可直接阻断伤害性刺激的传入^[12]。舒芬太尼作为 μ

阿片受体高选择性的激动药, 具有高受体选择性、高脂溶性等特点, 其镇痛作用明显强于芬太尼, 且安全范围宽^[13,14]。舒芬太尼有较独特的作用机理和药理学特点, 其可透过血脑屏障, 于短时间内在脑部起到有效的血药浓度, 因此其起效快速, 作用较芬太尼平稳^[15,16]。舒芬太尼能够减轻迷走神经反应, 减少突出释放, 增加迷走神经的紧张性, 其又可抑制甲状腺素和肾上腺素的分泌, 抑制应激反应及代谢^[17,18]。同时, 舒芬太尼可阻断气管插管时的机械刺激, 从而减轻气管插管所致的血流学波动,

保持平稳的生命体征^[19,20]。

既往研究报道^[21,22]小剂量阿片类药物对应激反应的控制效果欠佳,足量虽可有效抑制插管应激反应,但可能引起苏醒延迟、恶心呕吐等不良反应。加上患者个体差异性大,药物剂量对药物效应有一定影响,因此需明确最佳的给药剂量,从而在发挥良好作用的同时最大程度的降低对呼吸的影响^[23,24]。Narimani Zamanabadi M^[25]等研究表明小剂量舒芬太尼无法有效抑制插管反应,可能引起部分对抗反应,且需通过追加镇痛药达到手术镇痛作用。机体发生应激反应时可刺激儿茶酚胺的分泌,其中NA及ND变化较明显^[26]。本研究结果显示各组气管插管1 min及3 min后血浆NA及AD水平均增加,以0.4 μg/kg舒芬太尼组变化更明显,提示增加舒芬太尼剂量更能明显减轻全麻气管插管时的应激反应。

全麻气管插管时可引起血流动力学波动,加重心肌耗氧量,增加心律失常及心肌缺血等风险^[27]。心率及血压是评价机体血流动力学的重要指标,其中心率能够客观反映循环系统紧张程度。本研究数据显示各组基础值心率、平均动脉压无显著差异,气管插管1 min及3 min后各组心率及平均动脉压均上升,但0.5 μg/kg舒芬太尼组上升幅度较小,0.6 μg/kg舒芬太尼组心率及平均动脉压则明显低于基础值,提示小剂量舒芬太尼可能引起全麻气管插管期血流动力学波动,考虑与小剂量舒芬太尼对血管的收缩作用、镇静作用不明显,从而无法保持血流动力学平稳,但大剂量舒芬太尼则可能导致心血管抑制,对患者产生不良影响,应用0.5 μg/kg舒芬太尼组血流动力学无明显波动。

应激反应能够增加机体兴奋性,出现觉醒反应,BIS可自动分析及分级处理麻醉状态下患者的脑电图波形,以数字形式反映麻醉镇静深度,又可准确评价皮层功能状态和意识抑制程度,其结果准确可靠,现已广泛用于临床麻醉深度的监测。但既往研究报道麻醉状态下,麻醉深度和心率、血压等无明显相关性。临床为避免麻醉诱导时麻醉镇静程度过深或过浅,用BIS进行监测,本研究显示气管插管后1 min、3 min,常规芬太尼对照组BIS明显高于不同剂量舒芬太尼组,0.4 μg/kg舒芬太尼组BIS值又高于0.5 μg/kg及0.6 μg/kg舒芬太尼组,0.6 μg/kg舒芬太尼组BIS值相对较低,提示0.5 μg/kg舒芬太尼的麻醉深度适当,可有效抑制气管插管引起的应激反应,大剂量舒芬太尼可能引起麻醉加深。有关研究显示随着舒芬太尼用量的增加,能够导致苏醒延迟和呼吸抑制,延迟术后拔管时间,增加全身麻醉后并发症风险。本研究结果显示0.6 μg/kg舒芬太尼组自主呼吸恢复时间、呼吸睁眼时间和拔管时间较0.4 μg/kg及0.5 μg/kg组多,0.4 μg/kg和0.6 μg/kg舒芬太尼组相似,说明此剂量的舒芬太尼未影响患者苏醒期恢复,安全性较高,0.6 μg/kg舒芬太尼能够延长患者恢复时间。

药理学研究表明舒芬太尼的分布容积小,可快速经过血流屏障及神经细胞膜,加快在体外的效应,缩短终末消除期和体内消除期。但有研究显示部分患者予以舒芬太尼后可能发生麻醉恢复不及时,导致呼吸抑制^[28]。本研究结果显示0.4 μg/kg舒芬太尼组呛咳发生率相对较高,0.6 μg/kg舒芬太尼组恶心呕吐率则又高于其他剂量舒芬太尼组,可能与拔管、吸痰等刺激增强机体交感神经系统活性,从而引起血流动力学波动,增加呛

咳几率,尽管呛咳反应多呈一过性及短暂性,但剧烈咳嗽可能增加腹内压、眼内压和颅内压,引起严重并发症,增加围术期风险,大剂量舒芬太尼则增加药物不良反应可能性,引起恶心呕吐等不适。

综上所述,0.5 μg/kg舒芬太尼能够减轻直肠癌全麻气管插管应激反应,减少血流动力学波动,且无苏醒延长,不增加药物不良反应的发生。

参考文献(References)

- [1] Yamana I, Sakamoto Y, Ichikawa J, et al. Radical Surgery Following Chemotherapy in a Patient with Mesenteric Recurrence Associated with Hematoma upon ESD for Rectal Cancer Three Years Six months Later[J]. Gan To Kagaku Ryoho, 2019, 46(13): 2005-2007
- [2] Inoue T, Tei M, Mikuriya K, et al. A Case of Rectal Cancer with Multiple Liver Metastases Curatively Resected after Systemic Chemotherapy[J]. Gan To Kagaku Ryoho, 2019, 46(13): 2363-2365
- [3] Rajan S, Chandramohan R, Paul J, et al. Hemodynamic response to tracheal intubation in postlaryngectomy patients [J]. J Anaesthesiol Clin Pharmacol, 2019, 35(4): 504-508
- [4] Abdallah SI, Gaballah KM. Endotracheal Intubation Criteria and Stress Response: Airtraq versus Macintosh Laryngoscopes - A Prospective Randomized Controlled Trial [J]. Anesth Essays Res, 2019, 13 (3): 430-436
- [5] Gupta N, Kumar A, Jain A, et al. A Randomized Controlled Trial to Compare the Efficacy of Intravenous Dexmedetomidine and Clonidine as Adjuvants to Low Dose Opioid in Attenuation of Hemodynamic Response to Laryngoscopy and Tracheal Intubation [J]. Mymensingh Med J, 2018, 27(2): 389-396
- [6] Singh D, Yadav JS, Jamuda BK, et al. Oral Pregabalin as Premedication on Anxiolysis and Stress Response to Laryngoscopy and Endotracheal Intubation in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Double-Blind Study [J]. Anesth Essays Res, 2019, 13 (1): 97-104
- [7] Alimian M1, Mohseni M1, Faiz SHR1, et al. The Effect of Different Doses of Intrathecal Hyperbaric Bupivacaine Plus Sufentanil in Spinal Anesthesia for Cesarean Sections [J]. Anesth Pain Med, 2017, 7(6): e14426
- [8] Bourdon F, Simon N, Lannoy D, et al. Quality control and stability of ketamine, remifentanil, and sufentanil syringes in a pediatric operating theater[J]. Paediatr Anaesth, 2019, 29(2): 193-199
- [9] Montroni I, Ugolini G, Saur NM, et al. Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer[J]. Eur J Surg Oncol, 2018, 44(11): 1685-1702
- [10] Corcostegui SP, Commeau D, Galant J, et al. Intranasal sufentanil given in the emergency department triage zone for severe acute traumatic pain-a randomized double-blind controlled trial: comment [J]. Intern Emerg Med, 2019, 14(4): 635-636
- [11] Shigoka M, Koganezawa I, Yokozuka K, et al. A Case of Early Rectal Cancer Recurring as Liver Metastasis Nine Months after ESD[J]. Gan To Kagaku Ryoho, 2019, 46(13): 2285-2287
- [12] Hutchins JL, Leiman D, Rafique Z, et al. Pooled Dosing and Efficacy

- Analysis of the Sufentanil Sublingual Tablet 30 mcg Across Demographic Subgroups for the Management of Moderate-to-Severe Acute Pain[J]. J Perianesth Nurs, 2020, 35(1): 22-28
- [13] Oh SK, Lee IO, Lim BG, et al. Comparison of the Analgesic Effect of Sufentanil versus Fentanyl in Intravenous Patient-Controlled Analgesia after Total Laparoscopic Hysterectomy: A Randomized, Double-blind, Prospective Study [J]. Int J Med Sci, 2019, 16 (11): 1439-1446
- [14] Lemoel F, Contenti J, Cibiera C, et al. Intranasal sufentanil given in the emergency department triage zone for severe acute traumatic pain: a randomized double-blind controlled trial [J]. Intern Emerg Med, 2019, 14(4): 571-579
- [15] Deeks ED. Sufentanil 30 μg Sublingual Tablet: A Review in Acute Pain[J]. Clin Drug Investig, 2019, 39(4): 411-418
- [16] Vergari A, Di Muro M, De Angelis A, et al. Sublingual sufentanil nanotab patient-controlled analgesia system/15 mcg in a multimodal analgesic regimen after vertebral surgery: a case-series analysis [J]. J Biol Regul Homeost Agents, 2019, 33(5): 1615-1621
- [17] Reardon CE, Kane-Gill SL, Smithburger PL, et al. Sufentanil Sublingual Tablet: A New Option for Acute Pain Management[J]. Ann Pharmacother, 2019, 53(12): 1220-1226
- [18] Lee HM, Kil HK, Koo BN, et al. Comparison of Sufentanil- and Fentanyl-based Intravenous Patient-controlled Analgesia on Postoperative Nausea and Vomiting after Laparoscopic Nephrectomy: A Prospective, Double-blind, Randomized-controlled Trial[J]. Int J Med Sci, 2020, 17(2): 207-213
- [19] Lemoel F, Levraut J. Intranasal sufentanil given in the emergency department triage zone for severe acute traumatic pain: a randomized double-blind controlled trial-reply[J]. Intern Emerg Med, 2019, 14(4): 637-638
- [20] Lim L, Jang YE, Kim EH, et al. Comparison of the Effects of Sufentanil and Fentanyl in Intravenous Patient-Controlled Analgesia after Pediatric Moyamoya Surgery: A Retrospective Study[J]. Pediatr Neurol, 2020, 55(1): 36-41
- [21] Meuser T, Nardi-Hiebl S, Eberhart L, et al. Staff time requirements for postoperative pain management: Comparison of sufentanil sublingual tablet system and intravenous patient-controlled analgesia [J]. J Opioid Manag, 2019, 16(1): 33-39
- [22] Leykin Y, Laudani A, Busetto N, et al. Sublingual sufentanil tablet system for postoperative analgesia after gynecological surgery [J]. Minerva Med, 2019, 110(3): 209-215
- [23] Menezes DC, Vidal EIO, Costa CM, et al. Sufentanil during anesthetic induction of remifentanil-based total intravenous anesthesia: a randomized controlled trial[J]. Rev Bras Anestesiol, 2019, 69(4): 327-334
- [24] Pogatzki-Zahn E, Kranke P, Winner J, et al. Real-world use of the sufentanil sublingual tablet system for patient-controlled management of acute postoperative pain: a prospective noninterventional study[J]. Curr Med Res Opin, 2020, 36(2): 277-284
- [25] Narimani Zamanabadi M. Letter to: "The Effect of Different Doses of IHIntrathecal Hyperbaric Bupivacaine Plus Sufentanil in Spinal Anesthesia for Cesarean Sections"[J]. Anesth Pain Med, 2017, 7(6): e66202
- [26] Corcostegui SP, Commeau D, Galant J, et al. Intranasal sufentanil given in the emergency department triage zone for severe acute traumatic pain-a randomized double-blind controlled trial: comment [J]. Intern Emerg Med, 2019, 14(4): 635-636
- [27] Özgök A, Ulus AT, Karadeniz Ü, et al. Does uncontrolled diabetes mellitus affect cerebral hemodynamics in heart surgery [J]. Turk Gogus Kalp Damar Cerrahisi Derg, 2020, 28(1): 84-91
- [28] Schnider TW, Minto CF, Egan TD, et al. Correlation between bispectral index and age-adjusted minimal alveolar concentration [J]. Br J Anaesth, 2020, 124(1): e8
- [29] 白杰, 许玉本, 周海振, 等. 拇指背侧皮神经营养血管皮瓣修复对拇指远端软组织缺损的效果观察[J]. 现代生物医学进展, 2017, 17 (26): 5173-5176
- [30] 朱云开, 陈亚青, 刘卫勇, 等. 小儿拇指扳机指超声表现的初步研究[J]. 中华医学超声杂志(电子版), 2011, 8(8): 1759-1765

(上接第 2735 页)

- [21] Vasiliadis AV, Itsopoulos I. Trigger Finger: An Atraumatic Medical Phenomenon[J]. J Hand Surg Asian Pac Vol, 2017, 22(2): 188-193
- [22] 姜宇, 郭源. A1 滑车松解术治疗小儿拇指屈肌腱狭窄性腱鞘炎[J]. 山东医药, 2016, 56(39): 83-84, 85
- [23] Masquijo JJ, Ferreyra A, Lanfranchi L, et al. Percutaneous trigger thumb release in children: neither effective nor safe [J]. J Pediatr Orthop, 2014, 34(5): 534-536
- [24] 李瑞琦, 张国平, 李宜炯, 等. 自制“镰刀状”小针刀治疗小儿拇指屈肌腱狭窄性腱鞘炎 [J]. 现代中西医结合杂志, 2015, 24(19): 2086-2088
- [25] 叶晓品, 叶天申. 小针刀治疗小儿拇指屈肌腱狭窄性腱鞘炎 21 例体会[J]. 浙江中医药大学学报, 2013, 37(4): 462-463
- [26] 王易彬, 汤宇, 徐子涵, 等. 环线切割治疗小儿拇指狭窄性腱鞘炎
- 临床观察[J]. 中国骨与关节杂志, 2016, 5(3): 226-230
- [27] Kazmers NH, Stephens AR, Presson AP, et al. Cost Implications of Varying the Surgical Setting and Anesthesia Type for Trigger Finger Release Surgery [J]. Plast Reconstr Surg Glob Open, 2019, 7 (5): e2231
- [28] Bai RJ, Zhang HB, Zhan HL, et al. Sports Injury-Related Fingers and Thumb Deformity Due to Tendon or Ligament Rupture[J]. Chin Med J (Engl), 2018, 131(9): 1051-1058
- [29] 白杰, 许玉本, 周海振, 等. 拇指背侧皮神经营养血管皮瓣修复对拇指远端软组织缺损的效果观察[J]. 现代生物医学进展, 2017, 17 (26): 5173-5176
- [30] 朱云开, 陈亚青, 刘卫勇, 等. 小儿拇指扳机指超声表现的初步研究[J]. 中华医学超声杂志(电子版), 2011, 8(8): 1759-1765